EUVIMEDEUVIMED entdecken
Crossref

Nano Self-Assemblies of Caffeic Acid–Fibronectin Mimic a Peptide Conjugate for the Treatment of Corneal Epithelial Injury

Yiping Wu, Lulu Du, Xiaoning Xu, Yuhan Hu, Jia Liu, Jingwei Zhang, Lei Lei, Wenfang He, Zihao Sheng, Yuanao Ni, Jia Qu, Xingyi Li iD und 1 weitere

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Yiping Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, Chin…. Hauptthemen laut MEDLINE: Epithelium, Corneal, Corneal Injuries. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid corneal re-epithelialization is important for corneal wound healing. Corneal epithelial cell motility and oxidative stress are important targets for therapeutic intervention. In this study, we covalently conjugated the antioxidant caffeic acid (CA) with a bioactive peptide sequence (PHSRN) to generate a CA-PHSRN amphiphile, which was formulated into nanoparticular eye drops with an average size of 43.21 ± 16 nm. CA-PHSRN caused minimal cytotoxicity against human corneal epithelial cells (HCECs) and RAW264.7 cells, exhibited an excellent free radical scavenging ability, and remarkably attenuated reactive oxygen species (ROS) levels in H2O2-stimulated HCECs. The antioxidant and anti-inflammatory activities of CA-PHSRN were assessed in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. The results show that CA-PHSRN treatment effectively prevented LPS-induced DNA damage and significantly reduced the levels of LPS-induced pro-inflammatory cytochemokines (i.e., iNOS, NO, TNF-α, IL-6, and COX-2) in a dose-dependent manner. Moreover, using a rabbit corneal epithelial ex vivo migration assay, we demonstrated that the proposed CA-PHSRN accelerated corneal epithelial cell migration and exhibited high ocular tolerance and ocular bioavailability after topical instillation. Taken together, the proposed CA-PHSRN nanoparticular eye drops are a promising therapeutic formulation for the treatment of corneal epithelial injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelium, CornealCorneal InjuriesAnimalsHumansRabbitsAntioxidantsFibronectinsHydrogen PeroxideLipopolysaccharidesPeptide FragmentsPeptidesOphthalmic SolutionsCaffeic Acids

Stichwörter der Autor:innen

anti-inflammatoryantioxidantcorneal epithelial injurynanoparticleself-assembly

Substanzen

AntioxidantsFibronectinsHydrogen PeroxideLipopolysaccharidesPeptide FragmentsPeptidesOphthalmic Solutionscaffeic acidCaffeic Acids

Autor:innen und Institutionen

  • National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou 325027, China.

ORCID-Profile: Xingyi Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Du, L., Xu, X., Hu, Y., Liu, J., Zhang, J., Lei, L., He, W., Sheng, Z., Ni, Y., Qu, J., Li, X., & Jiang, J. (2023). Nano Self-Assemblies of Caffeic Acid–Fibronectin Mimic a Peptide Conjugate for the Treatment of Corneal Epithelial Injury. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00861

Vancouver

Wu Y, Du L, Xu X, Hu Y, Liu J, Zhang J, et al. Nano Self-Assemblies of Caffeic Acid–Fibronectin Mimic a Peptide Conjugate for the Treatment of Corneal Epithelial Injury. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00861

BibTeX
@article{Wu2023,
  author = {Wu, Yiping and Du, Lulu and Xu, Xiaoning and Hu, Yuhan and Liu, Jia and Zhang, Jingwei and Lei, Lei and He, Wenfang and Sheng, Zihao and Ni, Yuanao and Qu, Jia and Li, Xingyi and Jiang, Jun},
  title = {Nano Self-Assemblies of Caffeic Acid–Fibronectin Mimic a Peptide Conjugate for the Treatment of Corneal Epithelial Injury},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00861}
}
Kostenlos starten →